ClinicalTrials.gg
CompletedNCT00669955Updated Mar 16, 2017Results posted

Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy

A Phase 3 interventional study of Omeprazole, amoxicillin, clarithromycin and Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole in Helicobacter Infections, sponsored by Forest Laboratories. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-16.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims at evaluating efficacy and safety of quadruple therapy (bismuth, metronidazole, tetracycline and omeprazole: OBMT) vs triple therapy (amoxicillin, clarithromycin and omeprazole: OAC) in H. Pylori eradication. It is hypothesized that quadruple therapy will be comparable in efficacy to triple therapy. Subjects with confirmed H. pylori positive status will be randomized to one of the treatments described above. At week 6 and 10 follow-up visits, a urea breath test (UBT) will be performed to confirm eradication.

Read the detailed description

The study will include three phases: screening, treatment and follow-up. Screening: this phase will last a maximum of 30 days and subjects eligibility will be evaluated after informed consent signature. Endoscopy and Urea Breath test will be performed in addition to the baseline routine evaluations.

Treatment: Subjects assigned to OAC will be treated for 7 days. Those assigned to Pylera will be treated for 10 days. A randomization visit will take place on Day 0 and an end-of-treatment visit will take place between day 8 and 14.

Follow-up: includes two visits. approximately one and two months post-treatment. Eradication of H. Pylori will be confirmed through UBT, and resistance will be evaluated in case of treatment failure. These subjects will undergo an endoscopy.

02

Conditions studied

  • Helicobacter Infections

Keywords

  • H. Pylori
  • Quadruple therapy
  • Eradication rate
  • Multinational trial
  • Resistance to antibiotics
  • Subjects with confirmed Helicobacter Pylori infection
03

In context

Helicobacter Infections

53 studies on the registry are indexed under Helicobacter Infections; 9 are open to participants now.

This study's enrollment of 440 is above the median of 216 across 34 interventional studies indexed under Helicobacter Infections.

Browse Helicobacter Infections studies →

Lead sponsor

Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

First submitted before Forest Laboratories became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Positive H. Pylori status;
  • Presence of upper gastro-intestinal symptoms;
  • Mental and legal ability to sign .

Exclusion criteria

Exclusion Criteria:

  • Previous surgery of the GI tract;
  • impairment of renal or hepatic function;
  • Severe unstable cardiovascular, pulmonary or endocrine disease;
  • Barrett's oesophagus or high-grade dysplasia;
  • Dysphagia or vomiting as major symptoms.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
440 participants (actual)

Study arms

  • Active comparator
    OAC 7 days

    Triple therapy, given for 7 days at a dose of omeprazole 20 mg twice daily, amoxicillin 500 mg 2 capsules twice daily, and clarithromycin 500 mg 1 tablet twice daily

    Drug: Omeprazole, amoxicillin, clarithromycin

  • Experimental
    OBMT 10 days

    OBMT (Pylera), consisting of a 3 in 1 capsule, made of bismuth subcitrate potassium 120 mg, metronidazole 125 mg, and tetracycline 125 mg, administered as 3 capsules 4 times daily. Omeprazole 20 mg is administered twice daily.

    Drug: Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole

Interventions

  • DrugOmeprazole, amoxicillin, clarithromycin

    Drug pages: Omeprazole · Amoxicillin · Clarithromycin

    Triple therapy given for 7 days at a dose of omeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID

  • DrugPylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole

    Pylera is a three in one capsule containing bismuth subcitrate potassium 120 mg, metronidazole 125 mg and tetracycline 125 mg given as 3 capsules QID, with omeprazole 20 mg BID.

    Also known as: Pylera

06

What researchers measure

Primary outcomes

  1. Helicobacter Pylori Eradication Confirmed by Urea Breath Test

    H. pylori Eradication defined as a negative C13-UBT (urea breath test) result at both Week 6 and Week 10 follow-up visits.

    Time frame: Week 6 and week 10 follow-up visits

Secondary outcomes

  1. Number of Patients Experiencing Treatment Emergent Adverse Events.

    A treatment-emergent adverse event is defined as an event not present prior to exposure to the study medication or any event already present that worsens in either intensity or frequency following exposure to study medication up to 30 days after study discontinuation. All safety analysis based on the safety population.

    Time frame: at the end of treatment (day 8-14), week 6 and wek 10 follow-up visits.

  2. H. Pylori Eradication and Presence or Past History of Peptic Ulcers

    Eradication rates in the subset of patients with peptic ulcer (current or past history) at baseline are reported based on the per protocol population. Eradication must be confirmed at week 6 and week 10 by a negative Urea Breath Test conducted within the allocated windows.

    Time frame: Week 6 and week 10 follow-up visits

  3. Clarithromycin Resistance

    Eradication rates in subset of patients infected with a bacterial strain confirmed as resistant to clarithromycin at baseline. Resistance to clarithromycin defined as Minimum Inhibitory Concentration (MIC) of 1 ug/ml and above

    Time frame: Measured at baseline

  4. Metronidazole Resistance

    Eradication rates in subset of patients infected with a bacterial strain confirmed as resistant to metronidazole at baseline. Resistance to metronidazole defined as Minimum Inhibitory Concentration (MIC) above 8 ug/ml

    Time frame: Measured at baseline

  5. Overall Compliance to Study Medications

    Overall compliance: number of capsules dispensed - number of capsules returned/Number of prescribed capsules X 100. Percentages based on safety population

    Time frame: At the end of the treatment phase (days 8-14)

  6. Number of Patients With Bismuth Plasma Concentrations Above the Toxic Level

    Tolerability of OBMT with respect to plasma bismuth concentrations: number of patients with bismuth concentrations above the toxic level (50 ug per liter)

    Time frame: Baseline (both arms), end of treatment (Day 11-14) and end of study (Day 70) OBMT arm only

07

Results

Posted Aug 5, 2010

Participant flow

First patient in: 11 June 2008 Last patient out: 22 June 2009 Patients were recruited from clinics and hospitals located in seven European Countries: Germany, Poland, Italy, France, Ireland, Spain, United Kingdom.

Participant flow — Overall Study
MilestoneQuadruple Therapy (OBMT) 10 DaysTriple Therapy (OAC) 7 Days
Started218222
Completed204195
Not completed1427
Withdrew: Adverse event35
Withdrew: Death01
Withdrew: Withdrawal by subject23
Withdrew: Lost to follow-up57
Withdrew: Protocol violation27
Withdrew: Investigator sponsor judgement01
Withdrew: Not compliant with study drug/visit23

Outcome measures

PrimaryHelicobacter Pylori Eradication Confirmed by Urea Breath Test

H. pylori Eradication defined as a negative C13-UBT (urea breath test) result at both Week 6 and Week 10 follow-up visits.

Time frame:
Week 6 and week 10 follow-up visits
Reported as:
Number · Participants
Helicobacter Pylori Eradication Confirmed by Urea Breath Test
ParticipantsQuadruple Therapy (OBMT) 10 DaysTriple Therapy (OAC) 7 Days
Helicobacter Pylori Eradication Confirmed by Urea Breath Test166112
SecondaryNumber of Patients Experiencing Treatment Emergent Adverse Events.

A treatment-emergent adverse event is defined as an event not present prior to exposure to the study medication or any event already present that worsens in either intensity or frequency following exposure to study medication up to 30 days after study discontinuation. All safety analysis based on the safety population.

Time frame:
at the end of treatment (day 8-14), week 6 and wek 10 follow-up visits.
Reported as:
Number · Participants
Number of Patients Experiencing Treatment Emergent Adverse Events.
ParticipantsQuadruple Therapy (OBMT) 10 DaysTriple Therapy (OAC) 7 Days
Number of Patients Experiencing Treatment Emergent Adverse Events.101112
SecondaryH. Pylori Eradication and Presence or Past History of Peptic Ulcers

Eradication rates in the subset of patients with peptic ulcer (current or past history) at baseline are reported based on the per protocol population. Eradication must be confirmed at week 6 and week 10 by a negative Urea Breath Test conducted within the allocated windows.

Time frame:
Week 6 and week 10 follow-up visits
Reported as:
Number · Participants
H. Pylori Eradication and Presence or Past History of Peptic Ulcers
ParticipantsQuadruple Therapy (OBMT) 10 DaysTriple Therapy (OAC) 7 Days
H. Pylori Eradication and Presence or Past History of Peptic Ulcers1815
SecondaryClarithromycin Resistance

Eradication rates in subset of patients infected with a bacterial strain confirmed as resistant to clarithromycin at baseline. Resistance to clarithromycin defined as Minimum Inhibitory Concentration (MIC) of 1 ug/ml and above

Time frame:
Measured at baseline
Reported as:
Number · participants
Clarithromycin Resistance
participantsQuadruple Therapy (OBMT) 10 DaysTriple Therapy (OAC) 7 Days
Clarithromycin Resistance302
SecondaryMetronidazole Resistance

Eradication rates in subset of patients infected with a bacterial strain confirmed as resistant to metronidazole at baseline. Resistance to metronidazole defined as Minimum Inhibitory Concentration (MIC) above 8 ug/ml

Time frame:
Measured at baseline
Reported as:
Number · participants
Metronidazole Resistance
participantsQuadruple Therapy (OBMT) 10 DaysTriple Therapy (OAC) 7 Days
Metronidazole Resistance3828
SecondaryOverall Compliance to Study Medications

Overall compliance: number of capsules dispensed - number of capsules returned/Number of prescribed capsules X 100. Percentages based on safety population

Time frame:
At the end of the treatment phase (days 8-14)
Reported as:
Mean · participants
Overall Compliance to Study Medications
participantsQuadruple Therapy (OBMT) 10 DaysTriple Therapy (OAC) 7 Days
Overall Compliance to Study Medications97.58 ± 10.7197.47 ± 14.91
SecondaryNumber of Patients With Bismuth Plasma Concentrations Above the Toxic Level

Tolerability of OBMT with respect to plasma bismuth concentrations: number of patients with bismuth concentrations above the toxic level (50 ug per liter)

Time frame:
Baseline (both arms), end of treatment (Day 11-14) and end of study (Day 70) OBMT arm only
Reported as:
Number · participants
Number of Patients With Bismuth Plasma Concentrations Above the Toxic Level
participantsQuadruple Therapy (OBMT) 10 DaysTriple Therapy (OAC) 7 Days
Number of Patients With Bismuth Plasma Concentrations Above the Toxic Level0—

Adverse events

Collected over Adverse events were recorded starting at the signing of the informed consent until the final visit (Day 70) or early withdrawal visit. Serious adverse events were followed until 30 days after the patient had stopped study participation.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Quadruple Therapy (OBMT) 10 Days—4/216 (1.9%)98/216 (45.4%)
Triple Therapy (OAC) 7 Days—3/222 (1.4%)105/222 (47.3%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventQuadruple Therapy (OBMT) 10 DaysTriple Therapy (OAC) 7 Days
EczemaSkin and subcutaneous tissue disorders1/2160/222
Gastrointestinal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2160/222
Proteus infectionInfections and infestations1/2160/222
Renal artery stenosisRenal and urinary disorders1/2160/222
Renal failure acuteRenal and urinary disorders1/2160/222
SchizophreniaPsychiatric disorders1/2160/222
e coli urinary tract infectionInfections and infestations1/2160/222
AppendicitisInfections and infestations0/2161/222
Condition aggravatedGeneral disorders0/2161/222
DehydrationMetabolism and nutrition disorders0/2161/222
Most frequent other events
Most frequent other events
EventQuadruple Therapy (OBMT) 10 DaysTriple Therapy (OAC) 7 Days
DyspepsiaGastrointestinal disorders22/21630/222
DiarrheaGastrointestinal disorders14/21628/222
DysgeusiaNervous system disorders12/21622/222
Abdominal pain upperVascular disorders18/21616/222
HeadacheGastrointestinal disorders18/2167/222
NauseaGastrointestinal disorders14/2162/222

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Quadruple Therapy (OBMT) 10 DaysTriple Therapy (OAC) 7 DaysTotal
<=18 years000
Between 18 and 65 years184194378
>=65 years342862
Age, Continuous
Age, Continuous(years)Quadruple Therapy (OBMT) 10 DaysTriple Therapy (OAC) 7 DaysTotal
Mean48.53 ± 14.6447.95 ± 14.5248.24 ± 14.58
Sex: Female, Male
Sex: Female, Male(Participants)Quadruple Therapy (OBMT) 10 DaysTriple Therapy (OAC) 7 DaysTotal
Female105100205
Male113122235
Region of Enrollment
Region of Enrollment(participants)Quadruple Therapy (OBMT) 10 DaysTriple Therapy (OAC) 7 DaysTotal
Italy101020
Spain7613
France151732
Germany9291183
Poland9193184
United Kingdom358
08

Study locations

1 site
  • Dr. I. Orpen
    Bath, United Kingdom
09

References and documents

Publications

  • Malfertheiner P, Bazzoli F, Delchier JC, Celinski K, Giguere M, Riviere M, Megraud F; Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011 Mar 12;377(9769):905-13. doi: 10.1016/S0140-6736(11)60020-2. Epub 2011 Feb 21. Erratum In: Lancet. 2011 Nov 19;378(9805):1778. Dosage error in article text. PubMed 21345487 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Jul 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2008
First posted
May 1, 2008
Start
Jun 2008
Primary completionActual
Jul 2009
CompletionActual
Aug 2009
Results first posted
Aug 5, 2010
Last update
Mar 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00669955
Responsible party
Sponsor
First posted
May 1, 2008
Start date
Jun 2008
Primary completion
Jul 2009
Completion
Aug 2009
Results posted
Aug 5, 2010
Last update
Mar 16, 2017

Study contacts

Monique Giguère, PhD
study director · Axcan Pharma inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion